Evidence map›Paper›PMID 32383063›Full record

ArticleJournal of neuro-oncology2020

Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells.

Daniel T Nagasawa, Jian Yang, Prasanth Romiyo, Carlito Lagman, Lawrance K Chung, Brittany L Voth, Courtney Duong, Valerie A Kickhoefer, Leonard H Rome, Isaac Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Daniel T NagasawaDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Jian YangDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Prasanth RomiyoDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Carlito LagmanDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Lawrance K ChungDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Brittany L VothDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Courtney DuongDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Valerie A KickhoeferBiological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Leonard H RomeBiological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Isaac YangDepartments of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA. iyang@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlioblastoma prognosis remains grim despite maximal, multimodal management. Recent literature has demonstrated an increase in research devoted to experimental treatments, particularly those relying on the foundations of active immunotherapy with promising results. We hypothesize that the utilization of bioengineered recombinant vault nanoparticles coupled with glioma-associated antigens, such as the NY-ESO-1 peptide, may be capable of stimulating native dendritic cell (DC) maturation and inducing an anti-tumor response.

methodsImmature DCs were cultured from the bone marrow of 4-6-week-old C57BL/6 mice. The three treatment groups consisted of: (1) DC and media, (2) DC with mCherry vault, and (3) DC with NYESO and vault. DC maturity was assessed via flow cytometric evaluation of CD11c, CD86, and MHC-II. Increase in CD86 Median Fluorescence Intensity (MFI) was analyzed in the CD11c+CD86+MHC-II+ population to determine the extent of maturation

resultsOur findings suggest that CP-MVP-NY-ESO-1-INT recombinant vault nanoparticles are efficiently bioengineered with exceptional integrity, are quickly internalized by immature DCs for antigen processing, and result in DC maturation.

conclusionThis study reports our preliminary results, which demonstrate the feasibility and progress regarding our immunotherapeutic technique utilizing NY-ESO-1 packaged vault nanoparticles to prime DCs for subsequent anti-cancer therapies.

Indexed as

AnimalsAntibodiesAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBioengineeringDendritic CellsDrug Delivery SystemsGliomaMice, Inbred C57BLNanoparticlesRecombinant ProteinsAntibodiesAntigens, NeoplasmAntineoplastic Agents, ImmunologicalRecombinant ProteinsDendritic cellGlioblastomaImmunotherapyNanoparticlesNY-ESO-1 proteinVault ribonucleoprotein particles

Identifiers

PMID32383063
OpenAlexW3021349845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.